|
|
||||||||
Letters |
1
Groupe d'Etude des Substances Naturelles à Intérêt Thér., EA 491, Faculty of Pharmacy, Bordeaux, France ,
2
Centre d'Etudes et de Recherche sur les Xénobiot. , EA 1223, Faculty of Pharmacy, Poitiers, France
To the Editor:
Numerous epidemiological studies in France have shown a strong negative correlation between moderate red wine consumption and the incidence of cardiovascular disease (1)(2). Compared with other alcoholic beverages, red wine contains a much higher content of phenolic constituents. Frankel et al. (3) have shown that total phenolic compounds extracted from red wine inhibit the oxidation of human low-density lipoprotein (LDL) in vitro, which may provide an explanation for the "French paradox." In fact, increasing evidence suggests that oxidized LDL might be responsible for promoting atherogenesis.
Miller and Rice-Evans (4) examined a variety of red wines for total antioxidant activity and, based on the data of Frankel et al. (5) for the composition of wine, suggested that unidentified compounds must contribute to this total.
With the help of Vitis vinifera cell suspension obtained from Gamay Teinturier vine-plant, we isolated and characterized stilbenes (cis- and trans-piceid and trans-resveratrol) and anthocyanins (malvidin-3-O-ß-glucoside and peonidin-3-O-ß-glucoside) by spectrometric methods. Furthermore, we found evidence of production of astringin (a stilbene), which has never been reported as a constituent of Vitis vinifera and of wines (6)(7). Here, we report our study the antioxidant potency of these compounds isolated from Vitis vinifera cells by measuring the inhibition of lipid peroxidation induced by Cu2+ (IC50 = concentration at which one-half of the induced peroxidation is inhibited) in fresh human LDL preparation; we determined this by measuring the production of thiobarbituric acid-reactive substances (8). The lack of interference from the coloration of anthocyanins is verified by HPLC assays.
The IC50 of trans-resveratrol (Table 1
) is of similar magnitude to that previously reported
(9). The activity of the cis-isomer is 7 times
weaker, probably because of its nonplanar conformation.
|
Astringin (3-OH-trans-piceid) is 6 times more potent than trans-piceid, which confirms the major importance of catechol structure in antioxidant effect, as described for flavonoids. On the other hand, the conjugation of an OH group with a sugar decreased the antioxidant potential, according to the IC50 values of trans-resveratrol vs trans-piceid and astringinin vs astringin. The antioxidant activities of anthocyanins are similar to those of trans-resveratrol and astringin.
These data support previous work (3) suggesting that an array of phenolic substances in red wine may, because of their antioxidant properties, exert a protective effect against atherogenesis during a long period of moderate intake of red wine. We know little about the absorption, in vivo metabolism, and pharmacokinetics of phenols in wine. Consequently, we plan to produce 13C-labeled versions of these compounds to study both their absorption in human volunteers and their plasma antioxidant activity.
Acknowledgments
Research support was provided by the Region Aquitaine (grant no. 95 03 03 003) and the O.N.I. VINS, France. We thank R. Pontcharraud and A. Decendit for technical assistance and cell suspension maintenance, respectively.
Footnotes
References
The following articles in journals at HighWire Press have cited this article:
![]() |
S Prasad, N Kalra, S Srivastava, and Y Shukla Regulation of oxidative stress-mediated apoptosis by diallyl sulfide in DMBA-exposed Swiss mice Human and Experimental Toxicology, January 1, 2008; 27(1): 55 - 63. [Abstract] [PDF] |
||||
![]() |
L. Deluc, F. Barrieu, C. Marchive, V. Lauvergeat, A. Decendit, T. Richard, J.-P. Carde, J.-M. Merillon, and S. Hamdi Characterization of a Grapevine R2R3-MYB Transcription Factor That Regulates the Phenylpropanoid Pathway Plant Physiology, February 1, 2006; 140(2): 499 - 511. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |